Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Capricor Therapeutics (CAPR) EBT Margin (2016 - 2025)

Capricor Therapeutics has reported EBT Margin over the past 15 years, most recently at 194260.36% for Q1 2025.

  • Quarterly results put EBT Margin at 194260.36% for Q1 2025, down 19416242.0% from a year ago — trailing twelve months through Dec 2025 was 816055.45% (down 81590795.0% YoY), and the annual figure for FY2024 was 181.7%, down 9294.0%.
  • EBT Margin for Q1 2025 was 194260.36% at Capricor Therapeutics, down from 62.98% in the prior quarter.
  • Over the last five years, EBT Margin for CAPR hit a ceiling of 6.86% in Q4 2023 and a floor of 194260.36% in Q1 2025.
  • Median EBT Margin over the past 5 years was 338.64% (2022), compared with a mean of 15424.86%.
  • Biggest five-year swings in EBT Margin: soared 450477bps in 2021 and later plummeted -19416242bps in 2025.
  • Capricor Therapeutics' EBT Margin stood at 2482.54% in 2021, then surged by 68bps to 800.77% in 2022, then soared by 99bps to 6.86% in 2023, then crashed by -818bps to 62.98% in 2024, then crashed by -308362bps to 194260.36% in 2025.
  • The last three reported values for EBT Margin were 194260.36% (Q1 2025), 62.98% (Q4 2024), and 555.2% (Q3 2024) per Business Quant data.